What question did this study set out to answer?

To investigate factors in idecabtagene vicleucel infusion product associated with response in relapsed/refractory multiple myeloma.

December 8, 2025Blood

Nfkb signaling in idecabtagene vicleucel infusion product drives response in relapsed/refractory multiple myeloma

View Full Paper

Ask AI

Bookmark

Authors

Single-cell RNA sequencing uncovers robust NF-κB signaling correlating with outcomes in CAR-T therapy for multiple myeloma.

To investigate factors in idecabtagene vicleucel infusion product associated with response in relapsed/refractory multiple myeloma.
Conducted single-cell RNA sequencing on 40 patient infusion products
Analyzed CD4 and CD8 T cells separately using established gating methods
Performed flow cytometry on samples before CAR-T therapy
Evaluated NF-κB activation via selective IKKβ inhibition assays
Identified strong NF-κB signaling correlating with better progression-free survival
Noted differences in cellular compositions between responding and non-responding patients
Observed upregulation of pro-survival genes in durable responders
Characterized tumor microenvironment features associated with T cell fitness and responses

Noble et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark